Immunoglobulin therapy versus antibiotics after CAR-T cell treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study compares two ways to prevent infections in people who have had CAR-T cell therapy for B-cell leukemia or lymphoma. One group receives regular antibody infusions, and the other takes daily antibiotics. The goal is to see which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 80 years old.
- You have B-cell acute lymphoblastic leukemia or B-cell lymphoma.
- You have low antibody levels (gamma globulins less than 4 g/L) at the time of screening.
- You have received or are scheduled to receive CD19-targeted CAR-T cell therapy.
- If you can become pregnant, you must use reliable birth control during the study and for 12 months after CAR-T infusion.
- You must be able to sign an informed consent form (or have a legal representative do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.